首页> 美国卫生研究院文献>Elsevier Public Health Emergency Collection >Exploring the new horizons of drug repurposing: A vital tool for turning hard work into smart work
【2h】

Exploring the new horizons of drug repurposing: A vital tool for turning hard work into smart work

机译:探索药物用途的新视野:将辛勤工作变成明智工作的重要工具

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Drug discovery and development are long and financially taxing processes. On an average it takes 12–15 years and costs 1.2 billion USD for successful drug discovery and approval for clinical use. Many lead molecules are not developed further and their potential is not tapped to the fullest due to lack of resources or time constraints. In order for a drug to be approved by FDA for clinical use, it must have excellent therapeutic potential in the desired area of target with minimal toxicities as supported by both pre-clinical and clinical studies. The targeted clinical evaluations fail to explore other potential therapeutic applications of the candidate drug. Drug repurposing or repositioning is a fast and relatively cheap alternative to the lengthy and expensive de novo drug discovery and development. Drug repositioning utilizes the already available clinical trials data for toxicity and adverse effects, at the same time explores the drug's therapeutic potential for a different disease. This review addresses recent developments and future scope of drug repositioning strategy.
机译:药物的发现和开发是漫长且费钱的过程。成功地发现和批准用于临床使用的平均时间为12至15年,费用为12亿美元。由于缺乏资源或时间限制,许多铅分子没有得到进一步发展,其潜力也没有得到充分利用。为了使药物被FDA批准用于临床,在临床前和临床研究的支持下,它必须在目标靶区域具有最小的毒性且具有极好的治疗潜力。有针对性的临床评估未能探索候选药物的其他潜在治疗应用。重新定位或重新定位药物是一种漫长而昂贵的从头药物研发的快速且相对便宜的替代方法。药物重新定位利用毒性和不良反应的现有临床试验数据,同时探索该药物对另一种疾病的治疗潜力。这篇综述阐述了药物重新定位策略的最新发展和未来范围。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号